The clinical results and potential commercial value of drug conjugates, especially antibody drug conjugates (ADCs), have fueled the enthusiasm for M&A deals between companies and attracted widespread industry attention. Technological advances have also led to a collision of old and new concepts of drug conjugates, challenging even the current stage of drug conjugates concepts and technologies.